How effective is Letermovir?

Letermovir is an antiviral drug specifically designed to prevent cytomegalovirus (CMV) infection. It is mainly suitable for adult patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Such patients are at risk of CMV reactivation due to their suppressed immune systems, and CMV infection can lead to serious complications such as pneumonia, gastrointestinal disease, or hepatitis, which can even be life-threatening. Therefore, the application of letermovir is of great significance in reducing the risk of CMV infection in transplant patients.

CMV is a virus that commonly exists in the human body. It is usually in an inactive state and has little impact on healthy people. However, in patients with compromised immune systems, such as those receiving stem cell transplants, CMV may reactivate and cause infection, leading to transplant failure or other serious consequences. Letermovir plays an important role in the prevention of CMV by inhibiting the function of the CMV DNA terminase complex (pUL51, pUL56 and pUL89), thereby preventing the replication and spread of the virus.

A large clinical study of570 adult HSCT recipients showed that letermovir has significant efficacy in reducing CMV infection. The study results showed that at 24 weeks after transplantation, only about 38% (122/325) of patients receiving letermovir showed signs of CMV reactivation, compared with 61% (103/170) of patients receiving placebo. This data fully proves the superiority of letermovir in preventing CMV infection and shows that it can effectively reduce the risk of viral activation in transplant patients and improve the patient's transplant success rate and survival rate.

In addition, the safety profile of letermovir is also relatively good. Its main adverse reactions include nausea, vomiting, diarrhea, headache and fatigue. The overall tolerability is high, and no significant increase in adverse reactions was found compared with placebo. Therefore, letermovir has become an important choice for CMV prevention after allogeneic hematopoietic stem cell transplantation and is widely used around the world.

Reference materials:https://go.drugbank.com/drugs/DB12070